1 results match your criteria: "Pelotonia Institute for Immune-OncologyThe Ohio State University Wexner Medical CenterColumbusOhioUSA.[Affiliation]"
Article Synopsis
- CNPY2 is significantly overexpressed in liver cancer (HCC) and its levels are linked to poor survival outcomes in patients.
- The deletion of Cnpy2 in mice prevents HCC development induced by a chemical carcinogen, showing its crucial role in liver cancer progression.
- CNPY2 contributes to p53 destabilization and promotes oncogene expression through its interaction with ribosome proteins and enhancement of UPR pathways, indicating it as a potential therapeutic target for HCC.